+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (M-VEC) chemotherapy for invasive bladder cancer



DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (M-VEC) chemotherapy for invasive bladder cancer



Scandinavian Journal of Urology and Nephrology 36(1): 46-51



Objective: To investigate the value of DNA ploidy and S-phase fraction (SPF) as factors that could predict response and outcome of invasive transitional cell carcinoma (TCC) of the bladder to neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (MVEC) chemotherapy. Materials and Methods: Twenty-four patients with localized invasive TCC of the bladder (stages T3 to T4a, NoMo) were treated with neoadjuvant MVEC chemotherapy. DNA flow cytometry was performed in paraffin-embedded tissue obtained by transurethral resection before chemotherapy. Radical cystectomy specimens were utilized for complete pathologic staging. The tumors were subdivided into high- and low-SPF tumors according to their SPF value. DNA ploidy status was evaluated into two groups (diploidy and nondiploidy). Results: DNA ploidy was not correlated to the response to chemotherapy (p = 0.67), and overall or disease-free survival (p = 0.27 and p = 0.69, respectively). Major response (pathologic complete response and partial response) was more often found in the high SPF group than among tumors with low SPF (p = 0.02). High SPF tumors were significantly associated with increased overall and disease-free survival (p = 0.0056 and p = 0.0059, respectively). Conclusion: A high SPF, but not DNA ploidy, may be helpful to identify patient likely to respond and survive longer following neoadjuvant MVEC chemotherapy in the treatment of invasive bladder cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010413855

Download citation: RISBibTeXText

PMID: 12002357

DOI: 10.1080/003655902317259364


Related references

DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant M-VEC chemotherapy for invasive bladder cancer. European Urology 38(4): 519, 2000

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology 2013: 317190, 2013

Adjuvant systemic chemotherapy with cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin for locally advanced bladder cancer Results of a randomized, multicenter phase III study in Germany. Journal of Urology 169(4 Suppl.): 337, 2003

Study of neoadjuvant chemotherapy for invasive bladder cancer with MEC (methotrexate, epirubicin, cisplatin) therapy. Hinyokika Kiyo. Acta Urologica Japonica 47(4): 241-246, 2001

DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. Urology 43(6): 787-791, 1994

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Journal of Urology 163(5): 1602-1603, 2000

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. Journal of Clinical Oncology 29(16): 2171-2177, 2011

Survival analysis neoadjuvant methotrexate vinblastine adriamycin and cisplatin mvac chemotherapy in muscle invasive bladder cancer. Journal of Urology 147(4 Suppl.): 444A, 1992

Neoadjuvant phase II studies of modified methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer. Journal of Clinical Oncology 32(36): 4170, 2014

Updated results of a randomised controlled trial of neoadjuvant cisplatin , methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer. British Journal of Cancer 86(Suppl. 1): S23, 2002

Words of wisdom. Re: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. European Urology 60(4): 870-871, 2011

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 354(9178): 533-540, 1999

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. Journal of Clinical Oncology 32(18): 1895-1901, 2014

Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). Journal of Clinical Oncology 23(22): 4963-4974, 2005

Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin for locally advanced bladder cancer Results of a randomised, multicenter phase III study in Germany. European Urology Suppl.s 2(1): 126, 2003